ClinicalTrials.gg
Enrolling by invitationNCT07141329Updated Oct 27, 2026

SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

A Phase 2 interventional study of SPN-817 in Focal Onset Seizures, sponsored by Supernus Pharmaceuticals, Inc.. Enrolling by invitation at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 27, 2026Now Enrolling by invitationFirst site in Australia+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 395 studies in Seizures with a site in United States — 75 open to participants now, 93 under way, 21 of them phase 3. Seizures · United States.

Planned enrollment
111th of 306
100 · median 56
Started
2025
with 19 others
Phase 2
64 of 395
10 open now
Primary completion
2027-12
later than 49 of 91 live
Registered
372nd of 395
by date

Among the 395 studies in Seizures with a site in United States, this one is the 111th largest by planned enrollment of the 306 interventional ones that give a count, is one of 20 that started in 2025, is one of 64 in phase 2, reaches primary completion later than 49 of the 91 other live ones, and was the 372nd registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

75 of the 395 studies in Seizures with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Seizures with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.

Read the detailed description

This is a Phase 2b, multicenter, open-label extension, one-year, safety, tolerability, and efficacy study in adults who previously completed an applicable double-blind SPN-817 clinical study. This study will include a double-blind Dose Titration/Bridging Period of at least 58 days (8 weeks and 2 days) and up to 10 weeks in which SPN-817 will be titrated to the participant's maximum tolerated dose based on response. Following the Dose Titration/Bridging Period, participants will enter an Open Label Extension (OLE) Period of 42-44 weeks. When participants finish the OLE Period, they will initiate a Tapering Period (up to 4 weeks) followed by an End-of-Tapering Period video contact (VC) after the last dose of study drug. The duration of study treatment before starting the 4-week Tapering Period will be one year (52 weeks).

03

Conditions studied

  • Focal Onset Seizures

Keywords

  • focal seizures
  • focal epilepsy
  • open-label extension
  • anti-seizure medication
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completed antecedent SPN-817 double-blind study
  2. Taking a stable dosage regimen (maintained during the antecedent study) of at least one antiseizure medication (ASM) and no more than 4 ASMs

Exclusion criteria

Exclusion Criteria:

  1. Has current nonepileptic events that could be confused by the participant and/or study staff as epileptic seizures
  2. Has any suicidal behavior or suicidal ideation related to Item 4 (active suicidal ideation with some intent to act without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) based on the Columbia-Suicide Severity Rating Scale (C-SSRS) assessments in the antecedent study and at Visit 1 or more than one lifetime suicide attempt.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    SPN-817

    SPN-817, bid

    Drug: SPN-817

Interventions

  • SPN-817 starting at 0.25 mg bid up to 4.00 mg bid

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events

    The percent of participants who took at least one dose of SPN-817 and reported at least one adverse event during the 1-year SPN-817 Treatment Period

    Time frame: Week 1-Week 52

Secondary outcomes

  1. Percent change (PCH) from baseline in focal onset seizure frequency per 28 days over the 1-year SPN-817 Treatment Period

    Percent change in 28-day frequency of focal seizures during the 1-year Treatment Period relative to baseline

    Time frame: Baseline and Treatment Period (Week 1-52)

  2. Proportion of participants experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline

    Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the 1-year Treatment Period relative to baseline.

    Time frame: Baseline and Treatment Period (Week 1-52)

  3. Proportion of participants experiencing seizure freedom

    100% reduction in 28-day frequency of focal seizures during the Treatment Period relative to baseline

    Time frame: Baseline and Treatment Period (Week 1-52)

  4. Percentage of seizure-free days over the 1-year SPN-817 Treatment Period

    The number of seizure-free days reported for each participant divided by the total number of days with seizure data reported, multiplied by 100.

    Time frame: Week 1-Week 52

07

Study locations

8 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

Of 35 phase 2 interventional studies under Seizures, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Aug 26, 2025
StartActual
Jul 30, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Enrolling by invitation
changed Oct 27, 2026
Sites
7 sites added — first site in Australia
Show 7 added (6 United States, 1 Australia)
  • Center for Neurosciences · Tucson, United States
  • Focus Clinical Research · West Hills, United States
  • Ilumina Medical Research · Kissimmee, United States
  • University of Rochester Medical Center · Rochester, United States
  • Asheville Neurology Specialists · Asheville, United States
  • Thomas Jefferson University · Philadelphia, United States
  • The Alfred Hospital · Melbourne, Australia
Oct 27, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedPercent change (PCH) from baseline in quantifiable focal onset seizure frequency per 28 days over the 1-year SPN-817 Treatment PeriodTime frame: Baseline and Treatment Period (Week 1-52)
Oct 27, 2026
Contact
No study contact listed any more: removed c•••@supernus.com · •••5838; removed n•••@supernus.com · •••5328
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Recruiting→Enrolling by invitation
    7 sites added — first site in Australia
    Show 7 added (6 United States, 1 Australia)
    • Center for Neurosciences · Tucson, United States
    • Focus Clinical Research · West Hills, United States
    • Ilumina Medical Research · Kissimmee, United States
    • University of Rochester Medical Center · Rochester, United States
    • Asheville Neurology Specialists · Asheville, United States
    • Thomas Jefferson University · Philadelphia, United States
    • The Alfred Hospital · Melbourne, Australia
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedPercent change (PCH) from baseline in quantifiable focal onset seizure frequency per 28 days over the 1-year SPN-817 Treatment PeriodTime frame: Baseline and Treatment Period (Week 1-52)
    Contact No study contact listed any more: removed c•••@supernus.com · •••5838; removed n•••@supernus.com · •••5328
    + 3 other changes: verification date, registry dates and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07141329
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Jul 30, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Maciej Gasior, MD, PhD
study director · Supernus Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SPN-817

Start the discussion